Table 3.
Characteristics of subjects used for iTRAQ analysis. Saliva and blood samples were obtained prior to any treatments received by the subjects.
| Subject ID | Age | Diagnosis | Subject ID | Age | Diagnosis | Subject ID | Age | Diagnosis |
|---|---|---|---|---|---|---|---|---|
| N1 | 41 | NAD | B1 | 53 | Fibroadenoma | M1 | 75 | Invasive ductal carcinoma, Grade II, ER+/PR+/HER2- |
| N2 | 54 | NAD | B2 | 46 | Ductal ectasia | M2 | 64 | Invasive ductal carcinoma, Grade I, ER+/PR+/HER2- |
| N3 | 50 | NAD | B3 | 59 | Ductal hyperplasia; microcalcifications associated with benign ducts | M3 | 43 | Invasive ductal carcinoma, Grade II, ER+/PR+/HER2- |
| N4 | 47 | NAD | B4 | 52 | Benign fibroepithelial lesion | M4 | 71 | Invasive ductal carcinoma, Grade II, ER+/PR+/HER2- |
| N5 | 63 | NAD | B5 | 38 | Ductal hyperplasia | M5 | 68 | Invasive ductal carcinoma, Grade III, ER+/PR-/HER2- |
| N6 | 52 | NAD | B6 | 44 | Stromal fibrosis | M6 | 51 | Invasive ductal carcinoma, Grade III, ER-/PR-/HER2- |
| N7 | 48 | NAD | B7 | 64 | Atypical lobular dysplasia | M7 | 49 | Invasive ductal carcinoma, Grade II, ER+/PR+/HER2- |
| N8 | 65 | NAD | B8 | 52 | Ductal hyperplasia | M8 | 49 | Invasive ductal carcinoma, Grade II, ER+/PR+/HER2- |
| Mean ± SD | 52.5 ± 8.1 | Mean ± SD | 51 ± 8.3 | Mean ± SD | 58.8 ± 12.1 | |||
| Range | 41–65 | Range | 38–64 | Range | 43–75 |
NAD: no abnormality detected on mammogram; N1–N8: normal subjects; B1–B8: subjects with benign breast disease; M1–M8: subjects with malignant breast disease.